Protecting newborns in Rh(D)-incompatible pregnancies1

  • Protection against Rh(D) sensitisation1
  • Protection from risk of viral transmission1,2
  • Protection from accidental needle injury3

Rhophylac is a sterile solution of anti-D, also known as Rh(D) Immune Globulin or Rh factor, which protects against Rh-sensitisation in women with pregnancy and obstetric conditions, or for incompatible blood transfusions in Rh(D)-negative individuals.1

Haemolytic disease of the newborn (HDN) used to be a major cause of serious consequences or death in babies. HDN develops when the mother’s antibodies pass through the placenta and attack the red blood cells of her unborn infant, due to incompatibility between the blood types of an Rh-negative mother and her Rh-positive baby.4 For about 50 years, anti-D products have been used to prevent HDN, providing therapeutic antibodies to women to counter this effect.4

  • About 15% of white Caucasian people in Europe are Rh(D)-negative.5
  • About 60% of Rh-negative first-time mothers will have an Rh incompatible pregnancy.6
  • This Rh-sensitisation may or may not affect a woman’s first child but could create serious problems for subsequent children.6
  • Treatment with Rhophylac can prevent Rh-sensitisation, protecting newborn babies of Rh-negative mothers.1,4

Rhophylac® (human anti-D immunoglobulin) is indicated for:1

Pregnancy and obstetric conditions:
Prevention of Rh(D) isoimmunisation in Rh(D)-negative women.1

Incompatible transfusions:
Treatment of Rh(D)-negative adults, children and adolescents (0-18 years) after incompatible transfusions of Rh(D)-positive blood or other products containing red blood cells.1

Please confirm if you are a UK Healthcare Professional

You are now leaving

Do you wish to continue?